Hyaluronidase injections for tight, thick finger skin in systemic sclerosis
Tests hyaluronidase injections in adults with systemic sclerosis and stiff, tight fingers.
Plain-language title generated from the registry record
Registry title: Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma
Key facts
- Where
- Stanford, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Stanford UniversityStanford, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stanford University
- Trial code
- NCT07916324
- Record updated
- 6 November 2026
- Original description
Systemic sclerosis can cause the skin of the fingers to become thick and tight, a condition called sclerodactyly. This can make it difficult to bend, straighten, and use the fingers. This study will evaluate whether intradermal injections of hyaluronidase (Amphadase) can improve hand mobility and function and will assess treatment-related side effects.Read full original descriptionShow less
Intradermal Hyaluronidase for Sclerodactyly in Systemic Sclerosis: A Prospective Split-Hand Controlled Pilot Study
Systemic sclerosis can cause the skin of the fingers to become thick and tight, a condition called sclerodactyly. This can make it difficult to bend, straighten, and use the fingers. This study will evaluate whether intradermal injections of hyaluronidase (Amphadase) can improve hand mobility and function and will assess treatment-related side effects.
Approximately 10 adults with systemic sclerosis and sclerodactyly affecting both hands will participate at Stanford University. For each participant, one hand will be randomly selected by coin flip to receive hyaluronidase injections, while the opposite hand will serve as an untreated control. Participants may receive up to four injection sessions at baseline and approximately months 1, 2, and 3. Both hands will receive the same home exercise guidance throughout the study.
Participants will undergo assessments at baseline and months 1, 2, 3, and 6, including hand mobility and skin examinations, hand function questionnaires, and assessment of symptoms and adverse events. Researchers will compare changes between the treated and untreated hands. The investigator performing hand outcome assessments will be blinded to treatment assignment.
Inclusion: Adults aged 18 years or older; Documented diagnosis of scleroderma; Clinically evident bilateral sclerodactyly involving both hands,; Able and willing to comply with study visits and assessments; Able to provide written informed consent.
Exclusion: Known hypersensitivity to hyaluronidase or any component of the study drug; Active infection, acute inflammation, or another condition at a planned injection site that would make intradermal injection unsafe; Age younger than 18 years; Unable to provide informed consent; Absence of bilateral sclerodactyly sufficient to permit treatment and comparison; Pregnancy or anticipated pregnancy; Declines participation.